Table of Contents
Executive Summary
- The Eastern European healthcare environment
- Healthcare systems in Eastern Europe
- Therapeutic market analysis
- Leading players in Eastern Europe
Scope and methodology
Chapter 1 The Eastern European healthcare environment
- Summary
- Introduction
- Population profile
- Disease burden
- Macroeconomic comparison of Eastern European countries
- Economic landscape
- Healthcare spending
- Pharmaceutical sales growth
- Structural challenges to pharmaceutical marketers in Eastern Europe
- Key events
- Decentralization of the healthcare system leads to reduced expenditure
- Lack of funding in the Czech Republic leads to lack of innovation
- Implementation of cost-effectiveness improvement measures
- Strong performance of generic drug manufacturers
- Payers' acceptance of biosimilars will drive their uptake
Chapter 2 Healthcare systems in Eastern Europe
- Summary
- Introduction
- Profiles of healthcare systems across Eastern Europe
- Russia
- Healthcare system
- Pricing and reimbursement
- Political and regulatory status
- Ukraine
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Poland
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Romania
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- The Czech Republic
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Hungary
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Slovakia
- Healthcare system
- Pricing and reimbursement
- Regulatory status
- Slovenia
- Healthcare system
- Pricing and reimbursement
- Regulatory status
Chapter 3 Therapeutic market analysis in Eastern Europe
- Summary
- Pharmaceutical market overview
- Therapy area analysis
- Therapy area sales forecast
- Therapy area analysis by country
- Poland
- Russia
- Hungary
- Romania
- The Czech Republic
- Ukraine
- Slovakia
- Slovenia
- Leading brands
- Lovenox
- Coversyl
- Glivec
- Vastarel
- NeoRecormon
- Daflon
- Plavix
- Fraxiparine
- Augmentin
- Seretide
- Leading brands sales forecast
- Key brand analysis by country
- Poland
- Coversyl and Triatec
- Fraxiparine
- Zolafren
- Singulair
- Russia
- Actovegin, Merrem and Arbidol
- Essentiale
- Viagra
- Theraflu
- No Spa
- Hungary
- Romania
- Pegasys
- Vastarel
- Zyprexa
- Augmentin
- Coversyl
- Coversyl
- The Czech Republic
- Seretide
- Symbicort
- Remicade
- Ukraine
- Essentiale
- Actovegin
- Mezym forte
- Mucosolvan
- Traumel S
- Slovakia
- Erypo
- Optinate
- Mabthera
- Slovenia
- Zyprexa
- Ultop, Atoris and Vasilip
- Fosamax plus D
Chapter 4 Leading players in Eastern Europe
- Summary
- Introduction
- Leading players
- Analysis of key players in the Eastern Europe
- Novartis
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Novartis' s pipeline focus
- Strategic growth analysis
- Sanofi-Aventis
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Sanofi-Aventis' s pipeline focus
- Strategic growth analysis
- GSK
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- GSK' s pipeline focus
- Strategic growth analysis
- Servier
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Servier' s pipeline focus
- Strategic growth analysis
- Roche
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Roche' s pipeline focus
- Strategic growth analysis
- Key regional player in Eastern Europe
- Zentiva
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Zentiva' s pipeline focus
- Strategic growth analysis
- Leading players sales forecast
Leading players analysis by country
- Poland
- Russia
- Hungary
- Romania
- The Czech Republic
- Ukraine
- Slovakia
- Slovenia
Chapter 5 Appendix
- Anatomical Therapeutic Classification (ATC)
- A: Alimentary tract and metabolism
- B: Blood and blood-forming organs
- C: Cardiovascular system
- D: Dermatologicals
- G: Genito-urinary system and sex hormones
- H: Systemic hormonal preparations
- J: General anti-infectives systemic
- L: Antineoplastic and immunomodulating agents
- M: Musculo-skeletal system
- N: Nervous system
- R: Respiratory system
- S: Sensory organs
- T: Diagnostic agents
- V: Various
- Licensing status as per IMS Health
- Original brand
- Other brand
- Licensed brand
- Patent N/A brands
- Unbranded/generic product
- Glossary
- Index
List of Figures
- Figure 1.1: Czech Republic GDP distribution across different sectors, 2007
- Figure 1.2: Comparison of healthcare expenditure across Eastern European
countries
- Figure 1.3: GDP growth vs. pharmaceutical sales growth, 2006 - 07
- Figure 1.4: Structural challenges shaping Eastern European market
development
- Figure 2.5: Financing of healthcare system in Poland 53
- Figure 3.6: Eastern European pharmaceutical market share by countries, 2007
- Figure 3.7: Eastern European pharmaceutical sales by therapy area, 2007
($m)
- Figure 3.8: Top 10 sub-therapy area sales in the Polish pharmaceutical
market, 2007 ($m)
- Figure 3.9: Top 10 sub-therapy area sales in the Russian pharmaceutical
market, 2007 ($m)
- Figure 3.10: Top 10 sub-therapy area sales in the Hungarian pharmaceutical
market, 2007 ($m)
- Figure 3.11: Top 10 sub-therapy area sales in the Romanian pharmaceutical
market, 2007 ($m)
- Figure 3.12: Top 10 sub-therapy area sales in the Czech Republican
pharmaceutical market, 2007 ($m)
- Figure 3.13: Top 10 sub-therapy area sales in the Ukrainian pharmaceutical
market, 2007 ($m)
- Figure 3.14: Top 10 sub-therapy area sales in the Slovakian pharmaceutical
market, 2007 ($m)
- Figure 3.15: Top 10 sub-therapy area sales in the Slovenian pharmaceutical
market, 2007 ($m)
- Figure 4.16: Market share of top 10 and other companies in the Eastern
European market, 2007
- Figure 4.17: Novartis' s Eastern European market sales by therapy area, 2007
- Figure 4.18: Novartis' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.19: Sanofi-Aventis' s Eastern European market sales by therapy
area, 2007
- Figure 4.20: Sanofi-Aventis' s leading brand sales break-up across the
Eastern European countries, 2007
- Figure 4.21: GSK' s Eastern European market sales by therapy area, 2007
- Figure 4.22: GSK' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.23: Servier' s Eastern European market sales by therapy area, 2007
- Figure 4.24: Servier' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.25: Roche' s Eastern European market sales by therapy area, 2007
- Figure 4.26: Roche' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.27: Zentiva' s Eastern European market sales by therapy area, 2007
- Figure 4.28: Zentiva' s leading brand sales break-up across the Eastern
European countries, 2007
|
Related Report
|
View Cart
